Healthcare -
Medical - Instruments & Supplies - NASDAQ - US
$ 1.17
0 %
$ 58.3 M
Market Cap
-1.04
P/E
1. INTRINSIC VALUE
Balance Sheet
Akoya Biosciences, Inc.
| Current Assets | 76.7 M |
| Cash & Short-Term Investments | 35 M |
| Receivables | 13.8 M |
| Other Current Assets | 27.9 M |
| Non-Current Assets | 48.3 M |
| Long-Term Investments | 0 |
| PP&E | 13 M |
| Other Non-Current Assets | 35.3 M |
| Current Liabilities | 29.4 M |
| Accounts Payable | 8.76 M |
| Short-Term Debt | 3.28 M |
| Other Current Liabilities | 17.4 M |
| Non-Current Liabilities | 88 M |
| Long-Term Debt | 1.62 M |
| Other Non-Current Liabilities | 86.3 M |
EFFICIENCY
Earnings Waterfall
Akoya Biosciences, Inc.
| Revenue | 81.7 M |
| Cost Of Revenue | 33.8 M |
| Gross Profit | 47.9 M |
| Operating Expenses | 94.6 M |
| Operating Income | -46.7 M |
| Other Expenses | 8.64 M |
| Net Income | -55.4 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Akoya Biosciences, Inc.
| Net Income | -55.4 M |
| Depreciation & Amortization | 7.65 M |
| Capital Expenditures | -2.46 M |
| Stock-Based Compensation | 9.31 M |
| Change in Working Capital | 0 |
| Others | -5.7 M |
| Free Cash Flow | -46.6 M |
Wall Street Analysts Price Targets
Akoya Biosciences, Inc.
Wall Street analysts predict an average 1-year price target for AKYA of $4.7 , with forecasts ranging from
a
low of
$2.4 to a high of $7.5 .
AKYA Lowest Price Target
Wall Street Target
2.4 USD
105.13%
AKYA Average Price Target
Wall Street Target
4.7 USD
301.71%
AKYA Highest Price Target
Wall Street Target
7.5 USD
541.03%
4. DIVIDEND
ANALYSIS
AKYA does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Akoya Biosciences, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
30.7 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler®-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities
Akoya's technology to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research, funded through the Cancer Grand Challenges initiative The unprecedented scale of the initiative requires the high plex and high throughput of Akoya's PhenoCycler-Fusion platform to process thousands of patients' samples MARLBOROUGH, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, and SAMBAI, a team funded through the Cancer Grand Challenges initiative, today announced that Akoya's PhenoCycler-Fusion system will be the foundational spatial proteomics technology used to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research.
globenewswire.com
- 2 weeks ago
Tikvah Management Announces Intention to Vote AGAINST Quanterix's Proposed Merger with Akoya Biosciences
CHARLOTTE, N.C.--(BUSINESS WIRE)--Tikvah Management LLC (together with its affiliates, “Tikvah” or “we”), which owns approximately 1.5% of the outstanding common shares of Quanterix Corp. (Nasdaq: QTRX) (“Quanterix” or the “Company”), today announced that it intends to vote AGAINST the Company's proposed merger with Akoya Biosciences, Inc. (“Akoya”) (Nasdaq: AKYA) at the upcoming Quanterix Special Meeting of shareholders. As a significant investor in the Company since 2018, Tikvah believes the.
businesswire.com
- 4 weeks ago
Akoya Biosciences (AKYA) Reports Q4 Loss, Lags Revenue Estimates
Akoya Biosciences (AKYA) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.22 per share a year ago.
zacks.com
- 1 month ago
Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results
MARLBOROUGH, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2024.
globenewswire.com
- 1 month ago
Kent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today's Earnings Call
RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”) is a holder of 7.47% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX). Kent Lake has previously issued a public presentation detailing its opposition to the Company's proposed transaction (the “Transaction”) with Akoya Biosciences (“Akoya”) (NASDAQ: AKYA), and has also nominated three highly qualified, independent candidates for election to the Company's Board of Directors.
businesswire.com
- 1 month ago
Kent Lake Issues Letter to Quanterix Shareholders Regarding Opposition to the Company's Proposed Merger with Akoya Biosciences
RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”), a holder of 5.9% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), today highlighted its opposition to the Company's proposed merger (the “Merger”) with Akoya Biosciences (“Akoya”) (NASDAQ: AKYA). Kent Lake has also issued an open letter to all Quanterix shareholders outlining how the Merger significantly undervalues the Company and its intention to take all necessary step.
businesswire.com
- 2 months ago
Akoya Biosciences Unveils Strategic Product Roadmap, Powered by the New IO60 and Upcoming Neurobiology Panels
Rapid menu expansion with new high-plex human and mouse neurobiology panels joining the recently launched Human IO60 and Mouse FFPE IO Panels
globenewswire.com
- 2 months ago
Akoya Biosciences Selects Argonaut Manufacturing Services as IVD Manufacturing Partner
CARLSBAD, Calif.--(BUSINESS WIRE)--Argonaut Manufacturing Services (“Argonaut”), a leading contract development and manufacturing organization serving the biopharma and life sciences industries, and Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, announced today that Argonaut will act as the manufacturing partner for Akoya's IVD assays currently in development. This agreement builds on years of collaboration between Argonaut and Akoya, reflecting Argonaut's prove.
businesswire.com
- 2 months ago
Quanterix price target lowered by $4 at TD Cowen, here's why
Quanterix + Akoya Biosciences +0.39 (+14.72%)
https://thefly.com
- 3 months ago
AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akoya Biosciences, Inc. (NasdaqGS: AKYA) to Quanterix Corporation (NasdaqGM: QTRX). Under the terms of the proposed transaction, shareholders of Akoya will receive 0.318 shares of Quanterix for each share of Akoya that they own. KSF is seeking to determine whether this consideration and the process that led to.
businesswire.com
- 3 months ago
Shareholder Alert: Ademi LLP Investigates Whether Akoya Biosciences, Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Akoya (NASDAQ: AKYA) for possible breaches of fiduciary duty and other violations of law in its transaction with Quanterix. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Akoya stockholders will receive only 0.318 shares of Quanterix common stock for each share of Akoya common stock.
businesswire.com
- 3 months ago
AKYA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akoya Biosciences, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Akoya Biosciences, Inc. (NASDAQ: AKYA) to Quanterix Corporation for 0.318 shares of Quanterix common stock for each share of Akoya common stock is fair to Akoya shareholders. Halper Sadeh encourages Akoya shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersad.
businesswire.com
- 3 months ago
8. Profile
Summary
Akoya Biosciences, Inc. AKYA
COUNTRY
US
INDUSTRY
Medical - Instruments & Supplies
MARKET CAP
$ 58.3 M
Dividend Yield
0.00%
Description
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Contact
100 Campus Drive, Marlborough, MA, 01752
https://www.akoyabio.com
IPO
Date
April 16, 2021
Employees
205
Officers
Ms. Jennifer Kamocsay
Chief Legal Officer
Mr. Anthony Catalano
Senior Vice President of Operations
Mr. Rob C. Hart C.F.A., CFA, J.D.
Secretary
Mr. John Frederick Ek CPA
Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer
Dr. Niro Ramachandran Ph.D.
Chief Business Officer
Dr. Pascal Bamford Ph.D.
Senior Vice President of Research & Development and Laboratory Operations
Mr. Priyam Shah
Senior Director of Business Development & Investor Relations Strategy
Mr. Brian McKelligon
President, Chief Executive Officer & Director